Immunic, Inc. (NASDAQ: IMUX) is a Healthcare company (Biotechnology) with a market capitalization of $100M. The Maz Rating grades it against the other companies in its sector.
Immunic, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.33, Immunic, Inc. trades at 3.0x book value, with an EV/EBITDA of 0.3. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -136.3%, return on invested capital of -128.7% and a free cash flow yield of -97.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.28. Over the past 52 weeks the share price ranged from $5.06 to $17.43, with a beta of 1.48.
Immunic, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Immunic, Inc. (IMUX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 30.6% / 30% · Interest income / Revenue 109300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 30.6% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 109300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 30.6% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 109300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.11% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.0% / 33.33% · Receivables / Avg Assets (4Q) 0.96% / 33.33% · Interest income / Revenue 109300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.7% / 33.33% · (Cash+Recv) / Total Assets 97.0% / 33.33% · Interest income / Revenue 109300000.0% / 5% | Fail |
No. As of September 2026, Immunic, Inc. (IMUX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Immunic, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 109300000.0% of each dividend: Immunic, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.